Navigation Links
Pinnacle Biologics Inc. Announces Appointment of Bioprojet Pharma as Exclusive Distributor in Select European Countries
Date:4/18/2012

BANNOCKBURN, Ill., April 18, 2012 /PRNewswire/ --Pinnacle Biologics is pleased to announce the appointment of Bioprojet Pharma, effective March 15, 2012, as its exclusive distributor for ETHYOL (amifostine) and PHOTOFRIN (Porfimer Sodium) in select European countries.  

Ethyol is a cytoprotective agent indicated to reduce the incidence of moderate to severe xerostomia (dry mouth) following radiation treatment for head and neck cancer and to reduce cumulative renal toxicity associated with repeated administration of cisplatin in patients with ovarian cancer.  Bioprojet has rights to distribute Ethyol in France, Italy, Spain, Germany, the Benelux and other countries in the Pinnacle territory where the product is approved by the regulatory authorities.

Photofrin is a photo-activated drug and is indicated for the treatment of thoracic malignancies, specifically non-small cell lung cancer and esophageal cancer.  Bioprojet has rights to distribute the product initially in France, Germany and the United Kingdom.

About Pinnacle Biologics

Pinnacle Biologics Inc., a privately held bio-pharmaceutical company, specializes in revitalizing healthcare therapies to fulfill their true potential and to maximize favorable patient outcomes. The company is based in the U.S.A with its headquarters in Bannockburn, Illinois; and its European subsidiary, Pinnacle Biologics BV,is headquartered in Amsterdam and is the holder of the European Marketing Authorizations for Pinnacle products.

About Bioprojet Pharma

Bioprojet Pharma is a privately held European pharmaceutical company with is headquarters in Paris, France.  Bioprojet is a leading European research based specialty pharmaceutical company involved in the design and development of compounds from pre-clinical to Phase III.  The company markets pharmaceutical products across Europe.

Contact Information:
Pinnacle Biologics Inc.
2801 Lakeside Dr - Suite 209
Bannockburn, IL 60015
P: 1.847.283.7690
F: 1.847.283.7695
www.pinnaclebiologics.com


'/>"/>
SOURCE Pinnacle Biologics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pinnacle Oncology LLC Acquires Rights to Unique Radioprotector From the University of Chicago
2. Pinnacle Biologics Appoints ALKOPHARMA SA Its Exclusive Distributor For PDT (Photodynamic Therapy), in Select European Countries, Middle East And South East Asian Territories
3. Pinnacle Biologics Files for Orphan Drug Designation for PHOTOFRIN® in the Treatment of Patients with Malignant Mesothelioma.
4. Treatment of Patients With Malignant Mesothelioma Utilizing Photodynamic Therapy With Pinnacle Biologics Compound PHOTOFRIN® - Obtains FDA Orphan Drug Designation
5. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
6. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
7. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
8. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
9. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
10. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
11. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... 2017 Solentim, the developer of instrumentation ... of a major new product line called the ... VIPS has been developed for automatically seeding single ... part of the process to generate clonally-derived cell ... more reliable solution when compared to traditional single ...
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... ... with the Home Care Association of America (HCAOA). This agreement allows HCAOA members ... services, as well as discounts on Accreditation University (AU) educational resources that help ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
Breaking Medicine News(10 mins):